AlphAIAlphAI — Financial news for AI agents
tradingview.comJUL 311 min read$CGEN

CGEN Q2'26 Earnings: EPS estimate is (0.08) USD

Compugen Ltd. (CGEN) is scheduled to report Q2’26 results on Aug. 3 before market open, with release at 7:00 AM ET. The consensus estimates cited for Q2’26 are revenue of $1.28 million and EPS of -$0.08. The article references the company’s financials page for details.

Original reporting
tradingview.com
Published Jul 31, 2026, 11:00 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jul 31, 2026, 9:11 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
CGEN Q2'26 Earnings: EPS estimate is (0.08) USD — source image
Source · tradingview.com
Decision brief

The 30-second read

$CGENNeutralMed
01

Why it matters

Traders can use the stated consensus revenue ($1.28M) and EPS (-$0.08) to frame whether the upcoming print is likely to surprise and how to position into the event.

02

Market read

This is an earnings timing and consensus-expectations preview that can inform event-driven positioning and options implied-volatility expectations.

03

What to watch

The preview lacks guidance details, cash/burn commentary, and any pipeline or trial updates, which are often the real drivers of post-earnings repricing.

Relevance 6/10Novelty 5/10Timing: ahead of Aug 03 pre-market earnings release

Background

Compugen (CGEN) is set to announce Q2'26 results on Aug 03 at 7:00 AM ET (11:00 AM UTC).

Company-level read

Ticker impact

$CGENNeutralMedium confidence
Context

CGEN is scheduled to report Q2'26 results Aug 03 before the open, with consensus revenue of $1.28M and EPS of -$0.08.

Expected impact

Likely elevated pre-earnings volatility around Aug 03, with direction dependent on whether reported results beat or miss the -$0.08 EPS and $1.28M revenue expectations.

Evidence & confidence

This is a forward-looking earnings preview with specific consensus numbers, which can drive positioning and implied volatility into the print, but it does not include any new post-release datapoint.

Market effects

Sector

Biotech/small-cap earnings calendar risk for oncology/biopharma names, but no sector-wide new information is disclosed.

Regional

Primarily US pre-market positioning around a single small-cap earnings event.

Global

Limited, as the article is company-specific and does not cite global regulatory or macro catalysts.

Counterpoint

What could challenge this read

Negative consensus EPS does not guarantee downside; if expectations are already low, a modest beat could still trigger a relief rally.

Key entities

  • public_company
    CGEN

    Compugen Ltd., scheduled to report Q2'26 results before market open on Aug 03.

Read at source← All news

Related articles

AUG 3
$CGENMed

Compugen Reports Second Quarter 2026 Results

Compugen Ltd. (NASDAQ: CGEN) reported Q2 2026 results and a corporate update. The MAIA-ovarian trial of COM701 is progressing, with median progression-free survival interim data expected in Q1 2027. Partner AstraZeneca presented GEMINI-Hepatobiliary overall survival data for rilvegostomig (median 16.8 months). Cash was about $125.3M, funding operations into 2029. Q2 revenue was ~$2.6M vs ~$1.3M in 2025; net loss ~$7.0M.

prnewswire.com7 min
OCT 8
$VODMed

Vodafone seeks to cut UK costs by £1 billion by 2032

Vodafone aims to save £1 billion annually in UK costs by 2032, raising its target from £800 million. The company expects mid-to-high single-digit EBITDAaL growth and a threefold increase in operating free cash flow by 2032. CEO Margherita Della Valle cited confidence in the upgraded target.

finance.yahoo.com2 min
OCT 8
$LEVIHighAI 9/10

Levi Strauss Lifts Profit Guidance, but Tariff Refund Flatters the Beat

Levi Strauss (LEVI) raised its full-year profit guidance after Q3 adjusted earnings of $0.48 per share beat estimates, though revenue of $1.6B met expectations. The beat was partly due to a $79M tariff refund. Shares closed at $19.51, down 4.97% pre-earnings. The company plans to redeploy $60M into direct-to-consumer initiatives, which make up 45% of revenue. Guidance for gross margin and revenue growth was also adjusted.

asktraders.com2 min
OCT 8
$005930.KSMedAI 8/10

Record profits fail to impress Samsung investors

Samsung Electronics reported a record quarterly operating profit of 107.4 trillion won, up 782.5% year-over-year. Despite this, shares fell 2.42% as investors questioned the sustainability of earnings growth. Analysts are divided on the outlook, with some predicting a prolonged memory chip upcycle and others cautioning of a potential downturn. The company plans to return 50% of its free cash flow to shareholders between 2024 and 2026.

koreatimes.co.kr3 min
OCT 8
$WSMedAI 8/10

Worthington Steel Inc (WS) (Q1 2027) Earnings Call Highlights: Kloeckner Acquisition Drives

Worthington Steel Inc (WS) reported Q1 2027 earnings with $954M net sales, up 9% YoY, and adjusted EBITDA of $111M. The Kloeckner acquisition expanded operations but resulted in a net loss of $7M due to higher interest and purchase accounting impacts. Automotive and agriculture shipments grew, while energy and construction declined. Net debt stands at $1.9B. Management expects synergy benefits post-integration.

finance.yahoo.com3 min
OCT 8
$005930.KSMedAI 8/10

Foreign selling and ETF rebalancing drag South Korea stocks despite Samsung beat

South Korea's KOSPI index fell 2.62% to 6,625.93 despite Samsung Electronics(005930) reporting record earnings of 10.74 trillion won. Foreign and institutional selling, ETF rebalancing, and profit-taking drove the decline. Samsung's stock dropped 2.42%, while LG Energy Solution(373220) and Samsung SDI gained. Other major stocks like SK hynix(000660) and Hyundai Motor also fell.

biz.chosun.com2 min